JCRRF
Price
$4.57
Change
-$0.00 (-0.00%)
Updated
Jun 5 closing price
Capitalization
1.2B
SNYNF
Price
$103.00
Change
+$1.67 (+1.65%)
Updated
Jun 6 closing price
Capitalization
134.16B
Interact to see
Advertisement

JCRRF vs SNYNF

Header iconJCRRF vs SNYNF Comparison
Open Charts JCRRF vs SNYNFBanner chart's image
JCR PHARMACEUTICALS
Price$4.57
Change-$0.00 (-0.00%)
Volume$300
Capitalization1.2B
Sanofi
Price$103.00
Change+$1.67 (+1.65%)
Volume$100.42K
Capitalization134.16B
JCRRF vs SNYNF Comparison Chart
Loading...
View a ticker or compare two or three
VS
JCRRF vs. SNYNF commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JCRRF is a Hold and SNYNF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (JCRRF: $4.57 vs. SNYNF: $103.00)
Brand notoriety: JCRRF and SNYNF are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: JCRRF: 119% vs. SNYNF: 2%
Market capitalization -- JCRRF: $1.2B vs. SNYNF: $134.16B
JCRRF [@Pharmaceuticals: Major] is valued at $1.2B. SNYNF’s [@Pharmaceuticals: Major] market capitalization is $134.16B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JCRRF’s FA Score shows that 2 FA rating(s) are green whileSNYNF’s FA Score has 1 green FA rating(s).

  • JCRRF’s FA Score: 2 green, 3 red.
  • SNYNF’s FA Score: 1 green, 4 red.
According to our system of comparison, JCRRF is a better buy in the long-term than SNYNF.

Price Growth

JCRRF (@Pharmaceuticals: Major) experienced а 0.00% price change this week, while SNYNF (@Pharmaceuticals: Major) price change was +3.03% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.91%. For the same industry, the average monthly price growth was +5.75%, and the average quarterly price growth was +4.68%.

Industries' Descriptions

@Pharmaceuticals: Major (+2.91% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

FUNDAMENTALS
Fundamentals
SNYNF($134B) has a higher market cap than JCRRF($1.2B). JCRRF has higher P/E ratio than SNYNF: JCRRF (44.05) vs SNYNF (14.04). SNYNF YTD gains are higher at: 8.307 vs. JCRRF (0.000). SNYNF has higher annual earnings (EBITDA): 13.8B vs. JCRRF (7.45B). JCRRF has more cash in the bank: 13.3B vs. SNYNF (7.99B). SNYNF has less debt than JCRRF: SNYNF (21B) vs JCRRF (22.8B). SNYNF has higher revenues than JCRRF: SNYNF (46.1B) vs JCRRF (34.3B).
JCRRFSNYNFJCRRF / SNYNF
Capitalization1.2B134B1%
EBITDA7.45B13.8B54%
Gain YTD0.0008.307-
P/E Ratio44.0514.04314%
Revenue34.3B46.1B74%
Total Cash13.3B7.99B166%
Total Debt22.8B21B109%
FUNDAMENTALS RATINGS
SNYNF: Fundamental Ratings
SNYNF
OUTLOOK RATING
1..100
85
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
PROFIT vs RISK RATING
1..100
82
SMR RATING
1..100
74
PRICE GROWTH RATING
1..100
60
P/E GROWTH RATING
1..100
82
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DAPP15.151.21
+8.68%
VanEck Digital Trfmt ETF
JDST9.570.44
+4.82%
Direxion Daily Jr Gld Mnrs Bear 2X ETF
CFA86.580.59
+0.69%
VictoryShares US 500 Volatility Wtd ETF
AOR60.070.19
+0.32%
iShares Core 60/40 Balanced Allc ETF
RFEU69.33N/A
N/A
First Trust RiverFront Dynamic Eurp ETF

JCRRF and

Correlation & Price change

A.I.dvisor tells us that JCRRF and SNYNF have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that JCRRF and SNYNF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JCRRF
1D Price
Change %
JCRRF100%
N/A
SNYNF - JCRRF
8%
Poorly correlated
+1.65%
SCLX - JCRRF
4%
Poorly correlated
-2.47%
MIRA - JCRRF
2%
Poorly correlated
+2.19%
CSWYF - JCRRF
0%
Poorly correlated
N/A
VRBCF - JCRRF
-0%
Poorly correlated
N/A
More

SNYNF and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNYNF has been loosely correlated with SNY. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if SNYNF jumps, then SNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNYNF
1D Price
Change %
SNYNF100%
+1.65%
SNY - SNYNF
37%
Loosely correlated
+1.43%
NVSEF - SNYNF
24%
Poorly correlated
+1.97%
AZN - SNYNF
23%
Poorly correlated
+0.73%
JNJ - SNYNF
22%
Poorly correlated
+0.89%
NVS - SNYNF
21%
Poorly correlated
+0.20%
More